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Introduction
The primary goals of asthma treatment are to avoid
severe asthma exacerbations, to control symptoms
and to maintain normal lung function with the low-
est effective dose of medication so that unnecessary
adverse effects can be avoided. Global Initiative for
Asthma (GINA) guidelines recommend a stepwise
approach for asthma therapy that is based on achiev-
ing asthma control. Patients with persistent asthma,
not adequately controlled by maintenance therapy
with a low-to-medium dose of inhaled corticoster-
oids (ICS) alone, are treated with a low, and if
required, a medium or high dose of ICS combined
with a long-acting b2-adrenoceptor agonist (LABA),
plus as-needed reliever therapy with a short-acting
b2-adrenoceptor agonist (SABA). In patients not
achieving target control on ICS plus LABA therapy,
such as budesonide⁄formoterol or salmeterol⁄ﬂutica-
sone propionate single inhaler therapy, a third con-
troller, such as leukotriene receptor antagonist
(LTRA or theophylline), should be considered as a
further stepwise addition in therapy (1).
Budesonide is a potent corticosteroid that has
acute effects on inﬂammation (2) and airway respon-
siveness (3). Formoterol, a rapid LABA, has been
shown to improve asthma control and reduce severe
exacerbations when added to budesonide (4). This
rapid onset of effect has led to the development of
the budesonide⁄formoterol combination inhaler in a
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Objective: To study the effectiveness and safety of budesonide⁄formoterol (Symbi-
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talje, Sweden), a simpliﬁed management approach with one inhaler compared with
conventional best practice (CBP) with multiple inhalers in patients with persistent
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ﬁrst severe asthma exacerbation and number of severe asthma exacerbations.
Results: No difference between groups was seen in time to ﬁrst severe exacerba-
tion (p = 0.75). Exacerbation rates were low in both groups. A total of 12
patients in the Symbicort SMART
  group experienced a total of 14 severe asthma
exacerbations, and 19 patients in the CBP group experienced a total of 25 severe
asthma exacerbations (annual rate 0.07 vs. 0.13 p = 0.09). The mean daily dose
of ICS expressed in BDP equivalent was signiﬁcantly lower in the Symbicort
SMART
  group (including as-needed use) vs. in the CBP group (749 lg vs.
1059 lg; p < 0.0001). Mean scores in Asthma Control Questionnaire, 5 question
version improved signiﬁcantly in the SMART group compared with the CBP group
(p = 0.0026). Symbicort SMART and CBP were equally well tolerated. The mean
drug cost⁄patient⁄month was signiﬁcantly lower for the patients in the Symbicort
SMART group compared with patients receiving CBP (51.3 € vs. 66.5 €;
p < 0.0001). Conclusions: In Belgian patients, a simpliﬁed regimen using budeso-
nide⁄formoterol maintenance and reliever therapy was at least as effective at
improving clinical control compared with CBP with a signiﬁcantly lower ICS dose
and signiﬁcantly lower drug costs.
What’s known
Although SMART strategy has proved its efﬁcacy
and safety in asthma management in controlled
studies, data showing this concept may still be
operating in real clinical practice are still sparse.
What’s new
Our study shows that, in a setting close to real
clinical practice, Symbicort SMART is at least as
effective as best conventional practice in controlling
asthma but with a signiﬁcantly lower dose of ICS
and lower drug costs.
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In this real-life study, performed
in a wide range of asthma
patients suitable for combination
therapy, budesonide ⁄ formoterol
SMART was found to have similar
or better efﬁcacy and safety pro-
ﬁle as physicians free-choice of
guideline based maintenance
therapy (CBP) in maintaining or
improving asthma control and
reducing exacerbations. Budeso-
nide⁄ formoterol SMART also
reduced corticosteroid use, the
need for multiple controller thera-
pies and treatment costs.
Trial registration
NCT00290264.
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doi: 10.1111/j.1742-1241.2009.02185.x 1479single device (5) for use as both maintenance and
reliever therapy (SMART) (6).
A total of six double-blind comparative clinical
trials have consistently shown that the use of the
combination of budesonide⁄formoterol with a ﬁxed
maintenance dose plus as-needed reliever therapy
improved asthma control in adults and adolescents
by reducing exacerbations, improving lung function
and symptom control with a similar safety proﬁle to
higher doses of ICS alone (7,8) or similar or higher
ﬁxed dose ICS⁄LABA therapy with short-acting b2-
agonist reliever therapy (9–12). The efﬁcacy of
budesonide⁄formoterol for maintenance and reliever
therapy was also compared with any dose of salme-
terol⁄ﬂuticasone propionate plus salbutamol in an
open-label study that for the ﬁrst time provided phy-
sicians the freedom to titrate maintenance up or
down in accordance with normal clinical practice
with both regimen (13).
Although SMART strategy has proved its efﬁcacy
and safety in controlled studies and has also recently
been included in the GINA guidelines as a valid
option for both maintenance and reliever therapy
(1), data showing this concept may be operating in
real life are still limited. This 6-month study in out-
patients aged ‡ 12 years was intended to further vali-
date the efﬁcacy, the safety and the cost-effectiveness
of budesonide⁄formoterol (SMART) without changes
in maintenance therapy compared with CBP in a
real-life setting. The study compared the budeso-
nide⁄formoterol (SMART) concept with a conven-
tional stepwise treatment regimen in patients who
presented with symptoms on ICS or patients who
were symptomatic or asymptomatic on treatment
with combination therapy of ICS plus LABA and⁄or
LTRAs. Patients randomised to the Budesonide⁄
formoterol (SMART) arm were requested to main-
tain only the low maintenance dose of budesonide⁄
formoterol over the course of the trial with as-needed
adjustment if symptoms occurred. In this way, the
effectiveness of as-needed adjustment with Budeso-
nide⁄formoterol (SMART) could be compared with
physicians’ free choice of stepwise maintenance
therapies deﬁned as CBP.
Methods
Study design
This was a randomised, open-label, parallel-group,
multicentre study. An open randomised design was
necessary as an important part of the Budesonide⁄
formoterol (SMART) concept is the use of only
one inhaler. The complexity of treatment options
in the CBP arm with multiple controller therapies
allowed (ICS and ICS⁄LABAs at any dose, add-on
oral leukotriene antagonist or xanthines) also
excluded the possibility of blinding the comparator
treatment arm. The study consisted of a 2-week
run-in period followed by a 26-week randomised
treatment period.
The primary objective of the study was to compare
the efﬁcacy of Budesonide⁄formoterol (SMART) with
treatment according to CBP in adolescent and adult
patients with persistent asthma. The secondary objec-
tive was to collect safety data for treatment in the
two treatment groups by evaluating the incidence
and types of serious adverse events (SAEs) and dis-
continuations because of adverse events (AEs). In
addition, we compared the cost of asthma medica-
tion between the budesonide⁄formoterol (SMART)
group and the CBP group. For this purpose, a
randomised, open-label, parallel-group design was
selected at 194 centres in Belgium and Luxembourg
under the supervision of 305 investigators, 44 of
whom were specialists and 261 general practitioners.
The trial was carried out between December 2004
and June 2006.
Participants
The inclusion⁄exclusion criteria were designed to
select patients who presented with symptoms while
on treatment with ICS, or who where symptomatic
or asymptomatic on ICS and LABA therapy with or
without additional controller therapy, e.g. LTRAs.
The study population was therefore intended to be
consistent with the use of Budesonide⁄formoterol
(SMART) as an alternative to high dose ICS,
although combination therapy was allowed in the
CBP arm.
We enrolled out-patients of either gender aged
‡ 12 years who had been diagnosed with asthma
> 3 months and who were prescribed ICS at a dose
of ‡ 500 lg⁄day beclomethasone diproprionate
(BDP) equivalent ± any other controller therapies,
e.g. LABAs, LTRAs. To be eligible patients using ICS,
monotherapy also needed to use ‡ 3 inhalations of
as-needed medication for symptom relief during the
last 7 days before enrolment. We excluded patients if
they had used oral glucocorticosteroids (GCS) or if
they had experienced an asthma exacerbation requir-
ing a change in asthma treatment during the preced-
ing 14 days (Figure 1). Participants gave written
informed consent. For adolescents < 18 years old,
the written informed consent form was to be signed
by both the parent or legal guardian and the patient.
During the run-in period, all enrolled patients were
to continue on their usual asthma medications and
patients who experienced an asthma exacerbation
requiring change in asthma treatment during the
same period were withdrawn from the study.
Re-use of this article is permitted
in accordance with the Terms and
Conditions set out at http://
www3.interscience.wiley.com/
authorresources/onlineopen.html
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Patients started a 26-week study period receiving
either SMART [budesonide⁄formoterol
TM Turbu-
haler
TM (160⁄4.5 lg⁄inhalation, delivered dose)]
(AstraZeneca, So ¨derta ¨lje, Sweden), twice daily as
maintenance plus as needed in response to symp-
toms or CBP treatment. All investigators were
encouraged to provide CBP treatment according to
GINA guidelines with treatment changes allowed
(i.e. any locally approved maintenance therapy
excluding oral steroids) in response to increas-
ing⁄decreasing symptoms or deteriorating⁄improv-
ing lung function in the CBP group. During
treatment, visits were scheduled after 4, 13 and
26 weeks of study. Additional unscheduled visits at
the initiative of physician and⁄or patient were
allowed.
During the treatment period, SMART-treated
patients were not to use more than 10 inhalations
as-needed during any single day in addition to their
maintenance treatment. In the unlikely event, the
patient needed more as-needed medication on a single
day; the investigator was to be contacted for reassess-
ment of the patient’s condition. Patients were
instructed to rinse the mouth after intake of mainte-
nance medication (morning and evening) during the
treatment period, but not after intake of as-needed
medication. During the treatment period, asthma med-
ication other than budesonide⁄formoterol (SMART)
was only allowed for the treatment of exacerbations.
Enrolled n = 942
Excluded n = 34
Eligibility criteria not fulfilled
(n = 27)
Adverse event (n = 1)
Subject unwilling to continue (n = 5)
Subject lost to follow-up (n = 1)
Analysed (full analysis and 
safety analysis set) n = 450
0 excluded from analysis
Discontinued n = 27
Eligibility criteria not fulfilled (n = 10)
Adverse event (n = 4)
Subject unwilling to continue (n = 4)
Subject lost to follow-up (n = 5)
Other reason (n = 4)
Completed study n = 423 
450 allocated
SMART
0 excluded from analysis
Discontinued n = 14
Eligibility criteria not fulfilled (n = 7) 
Adverse event (n = 2)
Subject unwilling to continue (n = 1)
Subject lost to follow-up (n = 3)
Other reason (n = 1)
Completed study n = 444
458 allocated
CBP 
Analysed (full analysis and 
safety analysis set) n = 458)
Allocation
Analysis
Follow-Up
Randomised n = 908 
Figure 1 Trial proﬁle
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ing SMART and⁄or maintenance oral steroids was
considered as conventional best practice. Treatments
were individually prescribed at the discretion of the
investigator and within approved label for each prod-
uct. During the treatment period, the CBP patient
received the same instructions related to as-needed
SABA medication as speciﬁed in the SMART group
and as per normal practice, and patients were
instructed to rinse the mouth after intake of any
ICS-containing medication.
Outcomes
The data collection process was designed to inﬂuence
the patient and the physician behaviour as little as
possible during the study course to maintain a real-
life approach.
The primary outcome was the time to ﬁrst severe
asthma exacerbation deﬁned as deterioration in
asthma leading to at least hospitalisation⁄emergency
room (or equivalent) or oral GCS treatment for at
least 3 days.
Secondary outcome variables included the number
of severe asthma exacerbations, the mean use of
as-needed medication (reliever medication) and pre-
scribed asthma medications. Patients completed their
daily use of as-needed medication (i.e. total number
of inhalations per day) in a notebook during the last
14 days before each visit during the treatment per-
iod. The patients were also instructed to document
any changes in prescribed asthma medication during
the study period on an ongoing basis.
To assess lung function, pre and postbronchodila-
tor peak expiratory ﬂow (PEF) measurements were
performed with a Mini Wright
TM peak ﬂow meter
(Clement Clarke, Harlow, UK) in the GP clinic at
baseline and at 6-month. For patients enrolled by a
lung specialist, Forced Expiratory Volume in 1-s
(FEV1) measurements was performed in addition.
At both visits, PEF and FEV1 measurements were
performed according to standard procedures before
and after administration of two inhalations of bron-
chodilator (BD, Ventolin
TM pMDI 100 lg⁄inhala-
tion, Ventolin, GSK, Evreux, France). The highest
PEF and FEV1 value out of three attempts was
recorded.
Two patient-report outcome questionnaires were
used, the Asthma Control Questionnaire, 5 question
version (ACQ5) (14) and the Satisfaction with
Asthma Treatment Questionnaire (SATQ) (15). Both
were self-administered during the study visits and
completed before any other study-related procedures
took place.
The overall score for the ACQ5 was the mean of
the ﬁve responses. At least four out of the ﬁve ques-
tions must have been answered to provide a value.
The change from baseline to the average during the
treatment period (mean of Visits 3, 4 and 5) was cal-
culated for the ACQ5 score.
The SATQ was used to measure the patient’s sat-
isfaction with their inhaled asthma medication. The
SATQ has been validated for use from the age of
18. The questionnaire includes 26 questions that are
divided into four domains: effectiveness (eight ques-
tions), ease of use (seven questions), burden of
asthma medication (six questions) and side effects
and worries (ﬁve questions). The response options
for each question are assessed on a seven-point
scale. Negatively phrased items are reversed, so that
a higher score indicates higher satisfaction with
inhaled asthma treatment. The SATQ was adminis-
tered only at baseline and at 6-month. Patients were
reminded that they were scoring satisfaction with
their inhaled asthma treatment and not satisfaction
with other medical treatment or with the health
care system.
The cost of asthma medication used over the
entire study period was estimated for each patient,
based on information provided in the patient note-
book. The Belgian Centre of Pharmacotherapeutic
IBIP website was used to calculate the minimum
number of units of each medication which would
have been needed to be purchased, based on product
name and duration of use. Mean (with standard
deviation) and median costs per patient in each
treatment group were then determined.
To evaluate safety of treatment in both groups,
the number and percentage of patients with SAEs
and discontinuation of study treatment because of
AEs were analysed. Any indications in the notebook
of SAEs and⁄or discontinuations because of AEs
needed to be discussed by the investigator with the
patient.
Statistical methods
A sample size of 500 patients per treatment group (a
total of 1000 randomised patients) was required to
detect a difference between the two treatment groups
with 80% probability using a Log-rank test, under
the assumption that, at the end of the study, 11% of
the patients would have experienced a severe asthma
exacerbation in one treatment group and 6% of the
patients would have experienced a severe asthma
exacerbation in the other treatment group.
Time to ﬁrst severe asthma exacerbation was
described using Kaplan–Meier curves with treatments
compared using a Cox proportional hazards model
with treatment as a factor. The mean number of
severe asthma exacerbations per patient was com-
pared between treatments using a Poisson regression
1482 A comparison of SMART vs. CBP in asthma management
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study as an offset variable. The conﬁdence limits and
the p-value were adjusted for over dispersion. The
overall ACQ5 score, overall SATQ score, use of
as-needed medication, PEF, FEV1 and cost of asthma
medication were all compared between treatments
using separate analysis of variance models, with
treatment as factor and the baseline visit value as a
covariate. Safety data were analysed by means of
descriptive statistics. A p-value < 0.05 was considered
as statistically signiﬁcant.
Results
Demographics and baseline characteristics
A total of 942 subjects were enrolled in the study
and 908 subjects were randomised to either the
Budesonide⁄formoterol SMART group or the CPB
group. Overall, 867 subjects (95.5%) completed the
study. The most common reason for discontinuation
was the failure to meet eligibility criteria.
All patients were included in the analysis of safety
and efﬁcacy.
The demographics and key baseline characteristics
of study subjects are summarised in Table 1. Demo-
graphical characteristics were comparable in the two
treatment groups. The mean age of randomised
subjects was 43.1 years (range: 12–87 years). Their
mean daily dose of ICS during the run-in period
was 579 lg (1027 lg BDP equivalent). Asthma
severity at study entry was classiﬁed by investigators
as mild persistent (26.8%) of the study subjects),
moderate persistent (37.2%) or severe persistent
(35.8%).
Efﬁcacy
Severe exacerbations
The time to ﬁrst severe asthma exacerbation for each
group is plotted in Figure 2A. Only 2.7% of patients
who received the Budesonide⁄formoterol SMART
regimen and 4.1% of patients treated according to
conventional best practice experienced a severe
asthma exacerbation during treatment (Table 2).
Comparison of the time to ﬁrst severe asthma exac-
erbation in the two treatment groups showed no dif-
ference (p = 0.75). However, the incidence in both
groups was less than half that assumed when power-
ing the study (i.e. 6% vs. 11%). Twelve patients in
the Budesonide⁄formoterol SMART group experi-
enced a total of 14 exacerbations, and 19 patients in
the CBP group experienced a total of 25 exacerba-
tions (annual rate including all patients, i.e. 0.074 vs.
0.13 per patient-year p = 0.09). One patient in the
Budesonide⁄formoterol SMART group and four
patients in the CBP group had emergency room
treatment for a severe exacerbation. There were three
asthma-related hospitalisations, two in the SMART
group and one in the CBP group. The total number
of days of severe asthma exacerbation was greater in
the CBP group, 261 days vs. 138 days in the SMART
group. Furthermore, days with the use of oral corti-
Table 1 Demographical and baseline characteristics of the full analysis⁄safety set
Demographical or baseline characteristic
Treatment group
SMART (n = 450) CBP (n = 458) Total (n = 908)
Demographical characteristics
Gender (n and % of patients)
Male 198 (44.0) 188 (41.0) 386 (42.5)
Female 252 (56.0) 270 (58.9) 522 (57.5)
Age (years)
Mean 43.4 42.9 43.1
Range 12–87 13–85 12–87
Median time since diagnosis, years (range) 21.0 (0–86) 20.2 (0–78) 20.4 (0–86)
Baseline characteristics
Mean ICS dose⁄day before randomisation (range) 570 (100–2000) 589 (320–2000) 579 (100–2000)
BDP equivalent (range) 997 (200–4000) 1058 (450–4000) 1027 (200–4000)
Mean no. of as-needed inhalations⁄day (range) 1.09 (0–15) 1.02 (0–11) 1.06 (0–15)
As-needed free days, % (range) 60 (0–100) 61 (0–100) 60 (0–100)
All patients eligible for inclusion in the safety set were also eligible for inclusion in the efﬁcacy set. ICS, inhaled corticosteroids; CBP,
conventional best practice.
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more limited (132 days vs. 244 days, that is a reduc-
tion of 46%) in the Budesonide⁄formoterol SMART
group than in the CBP group.
Use of as-needed medication
The majority of patients in both groups had at least
1 day during which one or more as-needed inhala-
tion was required (264 out of 450 patients in the
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Figure 2 (A) Kaplan–Meier plot of time to ﬁrst severe asthma exacerbation. (B) Asthma control over time assessed by
Questionnaire (ACQ5). SMART = SMART; CBP = conventional best practice according to Global Initiative for Asthma
(GINA) treatment guidelines
Table 2 Number of patients with severe asthma exacerbations, total and by sub-criteria
Event SMART (n = 450) CBP (n = 458)
Severe asthma exacerbations (total) No. of patients 12 (2.7%) 19 (4.1%)
No. of events 14 25
Total no. of days 138 261
Oral GCS No. of patients 11 (2.4%) 16 (3.5%)
No. of events 13 22
Total no. of days 132 244
Emergency room treatment No. of patients 1 (0.2%) 4 (0.9%)
No. of events 1 4
Total no. of days 1 4
Hospitalisation No. of patients 2 (0.4%) 1 (0.2%)
No. of events 2 1
Total no. of days 10 15
GCS, glucocorticosteroids; CBP, conventional best practice.
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of 458 patients in the CBP group). Three patients in
the SMART group compared with nine patients in
the CBP group had at least 1 day with more than 10
as-needed inhalations.
Overall, mean daily as-needed inhalation use
remained about the same in both treatment
groups, and there was no statistically signiﬁcant
difference between groups in terms of the average
number of inhalations per day and as-needed free
days (Table 3).
Peak expiratory ﬂow and forced expiratory
volume
Pre- and post-BD PEF measurements were per-
formed at Visit 2 and Visit 5. For patients enrolled
by a lung specialist, pre- and post-BD FEV1 measure-
ments were also performed at these time points.
Mean PEF pre-BD increased from baseline for the
subjects in the SMART group by 13.23 l⁄min and for
the subjects in the CBP group by 10.84 l⁄min. The
mean PEF post-BD (l⁄min) increased from baseline
for the subjects in the SMART group by 9.17 l⁄min
and by 7.19 l⁄min for subjects in the CBP group.
There were no statistically signiﬁcant differences
between the two treatment groups for the mean pre-
BD (p = 0.56) and post-BD PEF (p = 0.60) values or
for the pre-BD (p = 0.48) and post-BD FEV1 values
(p = 0.33) (Table 3).
Patient reported outcomes
Asthma control assessed by questionnaire improved
in both groups from baseline. In the Budesonide⁄
formoterol SMART group, the mean ACQ5 score,
which assessed symptom control and activity limita-
tion during the treatment period, decreased by )0.30
compared with )0.17 in the CBP group (p < 0.01)
(Figure 2B, Table 3). Both groups showed similar
overall treatment satisfaction (improvement in SATQ
overall score) from enrolment to the end of the
study (Table 3).
Prescribed controller medication
All 458 patients treated according to conventional
best practice used ICS with the most commonly pre-
scribed additional controller medication, excluding
exacerbation treatment, being a long-acting b2-
agonist in combination with ICS in a single inhaler
(86%, n = 396). In addition, 7% of patients (n = 34)
used a separate long-acting b2-agonist and 27% of
patients (n = 125) used an LTRA as an additional
controller (Table 4). Among those 458 patients, at
the beginning of the study, 225 patients (49%) were
treated with budesonide⁄formoterol. A total of 95%
of the patients in the CPB group did not have modi-
ﬁcations (step up⁄step down) in their treatment dos-
age (Table 5).
The mean daily dose of inhaled steroid was signiﬁ-
cantly lower in the Budesonide⁄formoterol SMART
(including as-needed use) group vs. the CBP group
(482 vs. 589 lg⁄day for the actual doses, p < 0.0001
or 749 vs. 1059 lg when doses are expressed in BDP
equivalents, p < 0.0001).
Drug costs
Estimated drug cost used for asthma during the
treatment period were analysed for the two treatment
groups. Mean asthma drug cost⁄patient⁄month were
51.28 € for the patients in the Budesonide⁄formoterol
SMART group and 66.54 € for patients receiving
CBP (Table 6).
Drug costs linked to the use of asthma medication
were signiﬁcantly lower ()15.26 €; p < 0.0001) for
Budesonide⁄formoterol SMART group compared
with the CBP group (Table 6).
Safety⁄tolerability of the treatment
In this study, no clinically important differences
between the two treatment groups were observed
with regard to the overall pattern of reported SAEs
and withdrawal because of AEs. Both Budeso-
nide⁄formoterol SMART and CBP regimens were
well tolerated and no new or unexpected safety con-
cerns were identiﬁed. A total of 23 SAEs were
reported during treatment, 11 in the Budesonide⁄
formoterol SMART group and 12 in the CBP group.
Two patients in the Budesonide⁄formoterol SMART
group died during the course of the study, one by
suicide, the other following myocardial infarction.
None of the reported SAEs was considered to be
related to treatment by the investigator.
Adverse events led to discontinuation in two
patients (0.4%) in the SMART group and twp
patients (0.4%) in the CBP group. Only one subject
discontinued for a treatment-related event (sore
throat in a patient in the CBP group).
Discussion
The study conducted in Belgium and Luxembourg
conﬁrmed that Budesonide⁄formoterol SMART (one
inhalation bid as maintenance treatment plus inhala-
tions as needed in response to symptoms) is an effec-
tive therapy for asthma control compared with
physicians’ choice of CBP in a real-life setting.
Study procedures were aimed to minimally inﬂu-
ence patient’s behaviour and the pattern of the con-
tacts with their physician. Given the complexity of
treatment options in the conventional best practice
arm, an open-label study design was chosen. This
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without a separate as-needed inhaler, to be investi-
gated without the need for separate reliever therapy
as used in all previous double-blind studies. In the
conventional best practice arm changes of the main-
tenance dose and other treatment, changes were
permitted following any scheduled or unscheduled
contact with the physician, but the same low
maintenance dose of Budesonide⁄formoterol was
used throughout in the SMART arm, this was not
associated with any evidence of deteriorated asthma
control or raised exacerbation and use of reliever
therapy.
The incidence and severity of severe asthma exac-
erbations were similar for the two treatment arms,
but the overall incidence was far lower than assumed
when powering the study. However, the total number
of reported severe asthma exacerbations (14 vs. 25,
at a per anum rate per patient of 0.074 vs. 0.13,
respectively) and the total number of days of severe
asthma exacerbation (138 days vs. 261 days, respectively)
tended to be lower in the Budesonide⁄formoterol
SMART group compared with the CBP group.
In a previous open study comparing Budeso-
nide⁄formoterol SMART with titration of mainte-
nance treatment using salmeterol⁄ﬂuticasone
propionate (13), Budesonide⁄formoterol SMART sig-
niﬁcantly reduced severe exacerbations, but the over-
all incidence of events was substantially higher than
in this study. In our study, unlike in the study by
Vogelmeier et al. (13), patients with stable control
and no history of exacerbations were allowed to
enrol, and the maintenance treatment in the compar-
ator arm could be freely changed with other control-
ler drugs permitted, e.g. LTRAs. However, changes in
maintenance treatment in the Budesonide⁄formoterol
SMART arm or addition of other controller therapy
were not allowed. The lack of signiﬁcant differences
between Budesonide⁄formoterol SMART and CBP
with respect to time to severe exacerbation and exac-
erbation rates in this study and in other real-life
studies (16,17) is therefore likely to reﬂect a lack of
statistical power. This is linked to the low incidence
of events in the CBP arm because of the inclusion of
well-controlled patients and the added ﬂexibility of
treatment with a free choice of multiple maintenance
therapies or the addition of formoterol as reliever
therapy to the CBP arm, which is also effective in
reducing exacerbation risk (18). This study has, how-
ever, conﬁrmed that with no adjustment in mainte-
nance ICS⁄LABA or add-on therapy the SMART
approach had similar or better efﬁcacy compared
with multiple controller therapies and higher doses
of inhaled steroid used during CBP. The most com-
monly prescribed asthma medications, excluding
exacerbation treatment, in the 458 patients in the
CBP arm were a combination treatment of an ICS
and long-acting b2-agonist (86%) in a single inhaler
with 7% also using LABA via separate inhaler as
maintenance or reliever therapy. In addition, 27% of
patients in the CBP arm used LTRAs such that
approximately 20% of patients used of at least three
controller medications. Mean as-needed inhalation
was similar in both treatment groups. However, the
Budesonide⁄formoterol SMART group had lower
overall inhaled corticosteroid load. The daily ICS
Table 4 Prescribed maintenance therapy in the CPB
group
Prescribed maintenance medications n = 458
Inhaled comb of long-acting beta-2 agonist and ICS 396 (86%)
Leukotriene receptor antagonists 125 (27%)
Separate ICS inhaler 60 (13%)
Separate long-acting beta-2 agonist inhaler 34 (7%)
Inhaled long-acting anticholinergics 19 (4%)
Xanthines 14 (3%)
Mucolytics 5 (1%)
Cromoglycate 2 (0%)
ICS, inhaled corticosteroids; CBP, conventional best practice.
Table 5 Percentage of patients in CBP who stepped up
or stepped down
Stepped up Stepped down
Categories n (%) Categories n (%)
No 448 (97.82) No 447 (97.60)
Yes 10 (2.18) Yes 11 (2.40)
CBP, conventional best practice.
Table 6 Direct drug costs
Smart (€)
n = 450
CBP (€)
n = 458 p-value
Mean study drug cost
per patient per 6 months
297 400 < 0.001
Mean study drug cost per
patient per month
51 67 < 0.001
Mean study drug cost difference
per patient per month
)15 < 0.001
CBP, conventional best practice.
A comparison of SMART vs. CBP in asthma management 1487
ª 2009 Blackwell Publishing Ltd Int J Clin Pract, October 2009, 63, 10, 1479–1488dose was reduced signiﬁcantly in the Budeso-
nide⁄formoterol SMART arm vs. the CBP arm by
around 300 mcg⁄day (BDP equivalents). Further-
more days with the use of oral corticosteroids to
treat severe exacerbations were also reduced by 46%
in the Budesonide⁄formoterol SMART group com-
pared with the CBP group.
The patient’s perception of asthma control, weekly
symptoms and activity limitation assessed by a
validated asthma control questionnaire (ACQ5) was
improved to a greater extent over the study period
with Budesonide⁄formoterol SMART than with CBP,
although the two groups of patients were equally sat-
isﬁed with their treatment at the end of the study.
Of note is the fact that more than 95% of the
patients did not change the maintenance treatment
in the CBP group despite the fact that ACQ5 was
> 0.75 for most of the patients. However this trial
was undertaken 1 year before the publication of the
GINA that recommended the use of ACQ in clinical
practice to assess asthma control and adjust the
treatment accordingly. That might explain the rela-
tive passivity of the doctors in adjusting the dose of
maintenance treatment based on ACQ value.
In this study, overall Budesonide⁄formoterol
SMART treatment was well tolerated as CBP and
resulted in similar or better asthma control with less
intake of ICS compared with CBP. A post hoc analy-
sis also showed that drug costs linked to asthma
medication used over the entire study period were
signiﬁcantly lower by approximately 25% for the
Budesonide⁄formoterol SMART group. This is only
relevant if we actually calculate the direct healthcare
cost and not the drug cost alone. In this study, costs
linked to hospitalisation were very low because of a
few numbers of exacerbations. However, as hospitali-
sation days were lower in SMART group than in
CBP group, taking into account this parameter
would even strengthen the cost difference between
the two strategies. This cost-effectiveness of the
SMART strategy in Belgium⁄Luxembourg is keeping
with the results of a larger study conducted accord-
ing to a double-blind design (19).
In conclusion, in this real-life study performed in
a wide range of asthma patients suitable for combi-
nation therapy, we found Budesonide⁄formoterol
SMART to have similar or better efﬁcacy and safety
proﬁle as physicians free-choice of guideline based
maintenance therapy (CBP) in maintaining or
improving asthma control and reducing exacerba-
tions. Budesonide⁄formoterol SMART also reduced
corticosteroid use, the need for multiple controller
therapies and treatment costs.
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